cassava7
Senior Member (Voting Rights)
2022 has been an auspicious year for systemic lupus erythematosus (SLE). In February, the interferon receptor inhibitor anifrolumab became only the second targeted agent to be approved in Europe for treatment of SLE in more than six decades. A few months later, a 7-year-old Spanish girl who presented with symptoms of very early-onset SLE lead to the discovery of a causative mutation in the gene encoding the intracellular RNA sensor Toll-like receptor 7 (TLR7)—a finding that might eventually lead to new treatment strategies.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00163-1/fulltext
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00163-1/fulltext